Sleuth tracks over 22,000 Chinese programs, collected from China’s registries, regulators, stock exchanges, and social feeds, then translated and matched to the same drug and company records as Western programs.
Chinese programs show up in every biopharma team’s work: as the competitor in your landscape, the asset you might license, and the next wave of clinical data. Leave China out, and you’re missing half of the field.
84
companies licensed Chinese assets in 2025, up from 17 in 2021.
~50%
of the world’s ADCs, bispecifics, and CAR-T programs come from Chinese companies.
~2,500
Chinese assets are in late-stage development now, so a wave of clinical data is on its way.
375+
out-licensing deals from Chinese companies since 2021.
Sleuth analysis of China-originated programs and out-licensing deals, 2026.
China accepts more than 2,000 innovative IND applications a year, and those programs are disclosed first in Chinese: in patent filings, WeChat posts, Chinese medical meetings, and IND acceptances. Sleuth reads all of them, so you see a program when it’s disclosed, not months later when a database catches up.
Chinese biotechs usually file in China first, so a new program often shows up in a Chinese patent before anywhere else.
Some Chinese biotechs have no website and post pipeline news only on WeChat.
CSCO, CACA, and China’s other major meetings, where Chinese teams often present early data before it’s published.
China’s drug regulator lists each innovative IND it accepts, often a program’s first public record.
Sleuth reads 13 Chinese sources and China’s major medical meetings in the original Chinese, from the drug regulator’s trial registry to biotechs’ WeChat accounts.
China Drug Trial Registration Platform (CDE), ChiCTR, ITMCTR
Every drug trial China approves, often listed earlier and in more detail than on ChiCTR.
NMPA, CDE
Approvals, IND acceptances, and the breakthrough, priority, and conditional approval lists.
HKEXnews, CNInfo
Prospectuses and announcements from Hong Kong’s 18A biotechs and Shanghai’s STAR Market.
China National Intellectual Property Administration
Where Chinese biotechs usually file first on a new program.
Chinese-language journals, theses, and conference papers
Clinical and pharmacology work that’s largely missing from PubMed.
CSCO, CACA, the Chinese Society of Hematology, the Chinese Diabetes Society, the China Heart Congress, and more
Data presented in China, often before it’s published.
WeChat official accounts
Pipeline, financing, and trial updates, sometimes before any English release.
China CDC, China National Cancer Center, National Reimbursement Drug List (NHSA)
Patient numbers, and what China’s national insurance pays for.
Chinese banks and brokers, by kind
Analyst notes on Chinese companies and their programs, translated.
Chinese programs are spread across registries, exchange filings, and company posts, in Chinese and English. Sleuth translates every source, matches it to one record, and checks it against the others, so you can see where every value came from and how sure to be of it.
Every Chinese source is translated into English, and the original is one click away.
Chinese companies keep their Chinese and English names on one record, and a drug’s Chinese code, its INN, and its partner’s name all lead to the same program.
Every value shows its source and a confidence score. Sleuth checks Chinese records against Western ones, so you can see where they agree and where they don’t.
Connect Sleuth to Claude, ChatGPT, Copilot, or other AI tools, and it answers from the same knowledge base as Studio, with China’s registries, filings, and medical meetings already translated and matched. Chinese and Western programs come back in one answer, each with its source.
Claude searches the open web the day you ask. It finds the Chinese programs that made English news, but it can’t reach China’s trial registries, exchange filings, or WeChat posts.
Claude works from the same knowledge base as Studio, with China’s registries, filings, patents, and WeChat posts already translated and matched to the drugs and companies you know.
With Sleuth connected, AI tools found 63% more of the landscape in Sleuth’s benchmark.

The Wall Street Journal used Sleuth’s analysis of Chinese regulatory filings, press releases, and trial registries to show how quickly Chinese biotechs follow a Western breakthrough, and how many of those programs Western pharma licenses back.
Sleuth’s analysts publish on China from the same knowledge base you’d use, from whole drug classes to a single medical meeting.
China-originated ADCs supply 12 of the 14 Phase 3 ADC readouts at ESMO 2026.
13 of the 16 autoimmune T-cell engager deals since 2024 were sourced from China.
Western companies have licensed 13 Chinese GLP-1 assets back across 15 deals since 2021.
China originates about 1,045 of the roughly 2,045 ADC programs in development.
Ask about a target, a modality, or a competitor you already track, and see which Chinese programs Sleuth finds and where each one came from.
“Which Chinese companies have a [target] program, how far along is each, and has any been licensed outside China?”
“Which China-origin bispecifics in Phase 2 or later have no partner outside China yet?”
“Which Chinese programs started trials after [competitor]’s last readout in [indication]?”